How to Choose an SV2A Antibody: Validation Data for Epilepsy and Neurodegenerative Research

Why Is Proving SV2A Staining Authenticity So Difficult?

Immunohistochemistry of neural tissue runs into an unavoidable problem, which is proving that basal-like staining is genuine. Neuropil in brain tissue generates strong background on its own, and without a negative tissue control a positive result is difficult to defend. SV2A, as a synaptic vesicle marker, faces exactly this interpretive dilemma. This article reviews the molecular function, disease associations, and research directions of SV2A. It also presents publicly available validation data for the S0B60374 antibody as a reference for experimental design.

What Is SV2A?

SV2A, also known as synaptic vesicle glycoprotein 2A with the alias KIAA0736, is a synaptic vesicle transmembrane protein. It is widely distributed on synaptic vesicles throughout the brain and its cellular localization is annotated as synapse. Its core role in neurons is regulating neurotransmitter release, where it modulates the coupling efficiency between calcium influx and transmitter release during exocytosis.

Beyond that primary function, SV2A interacts with other synaptic proteins such as synaptotagmin. It is also thought to participate in galactose transport and in interactions with extracellular matrix components such as laminin. That synaptic localization makes SV2A a practical reference point whenever other synaptic markers return ambiguous signals. Its amino acid sequence is traceable to UniProt accession Q7L0J3.

Which Diseases Are Linked to SV2A?

Interest in SV2A began with pharmacology rather than pathology. It is the specific binding target of the antiepileptic drug levetiracetam. That finding connected SV2A directly to epilepsy pathology and to the mechanism of drug action, and it made the protein a repeatedly assayed target in neurological research.

Recent work points to a mitochondrial localization and function for SV2A, which may involve mitochondrial fusion and fission. Because mitochondrial dysfunction is a prominent feature of neurodegenerative diseases including Alzheimer's disease, this observation introduces a new research context. SV2A also stands out for its high abundance and specificity within synapses, which makes it useful as an imaging target for assessing synaptic density in neuroimaging research.

What Are the Typical Technical Challenges in SV2A Detection?

Apparent Molecular Weight Deviation

SV2A has a predicted molecular weight of approximately 83 kDa, yet it frequently appears as a signal above 100 kDa in immunoblots. Transmembrane structure and glycosylation both alter migration behavior in gels. Interpreting bands strictly against the predicted value therefore invites misreading of results.

Tissue Procurement and Fixation Determine Staining Quality

Neuropil in brain tissue is rich in membrane structures. When antigen retrieval conditions are unsuitable, diffuse background appears instead of specific staining. Synaptic density also varies between brain regions such as cortex and hippocampus, so interpretation must be anchored in anatomical expectation.

Negative Controls Are Indispensable

Demonstrating antibody specificity requires tissues predicted not to express SV2A as negative controls. Without that step, the credibility of a positive result is substantially weakened. Documenting which tissue served as the negative control also makes the staining rationale reproducible in other laboratories. Whether an antibody covers human, mouse, and rat samples simultaneously determines whether it can be applied directly to cross-species comparisons in disease models.

SV2A Recombinant Rabbit mAb (S0B60374) Validation Data

The validation design of the SV2A Recombinant Rabbit mAb (S-4049-16), catalog number S0B60374, addresses all three challenges described above. The product is a recombinant monoclonal antibody with a recombinant protein immunogen, purified by Protein A at a concentration of 0.5 mg/ml. The liquid format simplifies aliquoting. Species reactivity covers human, mouse, and rat, and validated applications are Western blot at 1:1000 and immunohistochemistry on paraffin sections at 1:2000.

Western Blot Validation

SV2A Western blot validation in mouse hippocampus and brain lysates

At a 1:1000 dilution, target bands were detected in mouse hippocampus, mouse brain, rat hippocampus, and rat brain tissue lysates. The predicted molecular weight is 83 kDa while the observed signal exceeds 100 kDa, consistent with the migration behavior described above. Recognizing this shift before interpreting blots prevents an incorrect negative call.

SV2A Western blot validation in rat hippocampus and brain lysates

Immunohistochemistry Validation

At a 1:2000 dilution, human cerebral cortex and human pancreas tissue both showed positive staining. Human kidney and human cervical squamous carcinoma were included as negative controls. Mouse and rat brain cortex and pancreas tissue also stained positive. Heat-mediated antigen retrieval was performed in Tris/EDTA buffer at pH 9.0 before staining.

SV2A IHC-P validation in human cerebral cortex with Tris/EDTA retrieval

SV2A IHC-P validation in human pancreas tissue

Product Specifications

The product ships with a Datasheet and a Certificate of Analysis for batch release. Sequence information is traceable to UniProt accession Q7L0J3, which makes it straightforward to document antibody source and validation evidence in the methods section of a publication.

Related Products

The product is supplied for research use only and is not intended for diagnostic or therapeutic procedures in humans or animals.

Summary and Outlook

The research value of SV2A lies in its status as a rare high-abundance, high-specificity marker of the synapse as a functional unit. That property lets it explain the site of action of antiepileptic drugs, serve as a window onto synaptic density, and enter the study of mitochondrial dysfunction. Detection requirements are correspondingly strict. Bands shift toward higher molecular weight, brain staining needs negative control support, and cross-species validation determines whether results transfer to disease models. Selecting a reagent with predefined positive and negative tissues therefore shortens method development rather than extending it. As epilepsy mechanism research and studies of synaptic damage in neurodegenerative disease advance, expectations for SV2A data that can be checked and reproduced will only rise.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

ANT BIO PTE. LTD. supplies high-quality reagents and solutions for life science research. Our sub-brands cover the full research workflow: Starter for antibodies and immunological assay kits, UA-Bio for recombinant proteins and drug discovery solutions, and Absin for general reagents and other detection kits. Explore our product portfolio at www.antbioinc.com.

Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.